Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
adalimumab
biologic drugs
hidradenitis suppurativa
paradoxical psoriasis
therapy
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
15
09
2022
received:
15
06
2022
accepted:
25
09
2022
pubmed:
30
9
2022
medline:
21
12
2022
entrez:
29
9
2022
Statut:
ppublish
Résumé
Adalimumab is the only biological drug approved to date for the treatment of moderate and/or severe hidradenitis suppurativa. Adverse events reported during therapy include paradoxical psoriasiform reactions. No guidelines are currently available for the management of this clinical condition. The aim of this paper is to describe the incidence and clinical features of paradoxical psoriasiform eruptions occurring during treatment with adalimumab in patients with hidradenitis suppurativa and to report real-life experience in management and the possible role of other biologic agents for the treatment of both conditions.
Identifiants
pubmed: 36175129
doi: 10.1111/dth.15866
pmc: PMC10078212
doi:
Substances chimiques
Adalimumab
FYS6T7F842
Biological Products
0
Biological Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15866Informations de copyright
© 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
Références
Dermatol Ther. 2021 Nov;34(6):e15116
pubmed: 34459075
Dermatol Ther. 2020 Nov;33(6):e14180
pubmed: 32790040
N Engl J Med. 2016 Aug 4;375(5):422-34
pubmed: 27518661
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
Br J Dermatol. 2021 May;184(5):966-967
pubmed: 33301601
JAMA Dermatol. 2019 Sep 01;155(9):1022-1027
pubmed: 31290938
J Am Acad Dermatol. 2020 May;82(5):1045-1058
pubmed: 31604104
Dermatol Ther. 2021 May;34(3):e14930
pubmed: 33665949
Dermatol Ther. 2022 Dec;35(12):e15866
pubmed: 36175129
Int J Dermatol. 2022 Apr;61(4):e126-e129
pubmed: 34151438
Br J Dermatol. 2018 Jan;178(1):281-283
pubmed: 28444990
Nat Commun. 2018 Jan 2;9(1):25
pubmed: 29295985